UCB's Global Corporate Website

Sales are on track and our pipeline looks healthy

Posted by
Antje Witte, Investor Relations
UCB’s total revenue increased by 2% to €1,706 million, thanks in large part to combined sales of our main rheumatoid arthritis, epilepsy and Parkinson’s disease products which reached €413 million (an increase of 45%).

Those of you who (like me) enjoy the numbers will want to know that the company’s underlying profitability (EBITDA) is: €347 million. Core earnings per share are €1.09 after €1.44 in the first half of 2011.

The important thing at this point of the year is to see that the financial outlook for 2012 is slightly updated. Total revenue is now expected to exceed €3.2 billion (previously approximately €3.1 bn), recurring EBITDA in the range of €630-660 million (unchanged) and core earnings per share are expected at approximately €1.70 (previously €1.60-1.70).

From my daily dealings with capital market professionals I know tomorrow’s pipeline is often as important as today’s earnings. I am seeing more and more interest in our potential projects of the future and I’m personally excited about potential new treatment options for postmenopausal osteoporosis, lupus and epilepsy which are at the latter stages of clinical development. We also hope to have headline results later this year for another rheumatoid arthritis drug candidate which is in phase 2b clinical trials.

Add to that some good news from last month since US-based patients have access to our Parkinson’s disease and restless legs syndrome medicine. This inspires us to continue investing in innovative therapies in the areas where UCB has established strong expertise.

We say it and we live it: patients are at our heart in everything we do. That’s why it is so gratifying that 354,000 patients have been treated with our three core medicines to date. Our ambition to reach more than 1.5 million patients with these three medicines is on course.

In short, mid-way through the year, the numbers are pointing in the right direction and our pipeline offers more. So a good time to enjoy your summer break!

For more information, please contact Antje Witte.

Leave a Comment

By submitting your personal data, you agree with UCB's Data Privacy Policy. Furthermore, for more information on the terms of use of this website please visit our Legal Notice, accessible here.